北大医药换新总裁，近百人围堵办公大楼问题待解

Group 1: Management Changes - The board of North China Pharmaceutical (000788) appointed Xu Xiren as the new president and Yu Mengchuan as the executive vice president, effective from the date of the board meeting approval until the end of the current board term [1] - Xu Xiren, born in April 1979, holds a master's degree and is the chairman and general manager of New Advantage Industry Group Co., Ltd. He indirectly holds 132 million shares of the company, accounting for 22.22% of the total share capital, making him the actual controller of the company [2] - Yu Mengchuan, born in September 1972, has a graduate degree and has held various managerial positions within North China Pharmaceutical and its subsidiaries [2] Group 2: Historical Issues - On July 1, North China Pharmaceutical reported disruptions at its office caused by nearly a hundred retired employees, which severely affected administrative operations [3] - The company stated that this incident did not impact its production and operational order significantly, and it is working to minimize the effects [3] - North China Pharmaceutical has called for the restoration of the rule of law and supports resolving issues through legal means [3] Group 3: Financial Performance - North China Pharmaceutical's revenue for 2024 was 2.06 billion yuan, a decrease of 6.1% year-on-year, while net profit was 138 million yuan, a significant increase of 211.1% [4] - The first quarter of 2025 saw revenue of 502 million yuan and a net profit attributable to shareholders of 45.64 million yuan [4] - The company reported a total of 772 employees, with 744 receiving salaries, and indicated that there were no retired employees for whom the parent company and major subsidiaries needed to bear costs [4] Group 4: Recent Developments - Since the change of actual controller in December 2024, North China Pharmaceutical has experienced frequent personnel changes [5] - The resignation of the previous president, Yuan Pingdong, was noted as significant, given his contributions to the company's profitability [6] - The new management faces the challenge of addressing historical issues stemming from past commitments and responsibilities following the company's restructuring [6]